VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., and makers of ACUVUE® Brand Contact Lenses, today announced the “ACUVUE® 1·DAY Contest,” which will bring five winners to Los Angeles to meet and be mentored by one of five top teen icons, including musician Joe Jonas, all-American actress Meaghan Martin, singing phenom Charice, world champion runner Allyson Felix and actor Sterling Knight.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/acuvue/50390/
VISTAKON® Division of Johnson & Johnson Vision Care, Inc., and the makers of ACUVUE® Brand Contact Lenses, today revealed the 2012 celebrity ensemble for this year’s “ACUVUE® 1-DAYContest.” The roster of celebrity mentors includes inspirational pop star Demi Lovato, musician Joe Jonas, breakout television star Tyler Blackburn, all-American actress Meaghan Martin and world champion sprinter Allyson Felix. The contest, now in its second year, will give five winners the chance to meet and be mentored for a day by one of the five teen icons.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55568-acuvue-brand-contact-lenses-launches-the-2012-acuvue-1-day-contest
Representing the leading edge of a wave of new products and technologies, Acura today unveiled three new vehicles at the North American International Auto Show, including a concept version of the all-new gateway to the Acura brand, the ILX luxury compact sedan; a prototype of the 2013 RDX crossover sport utility vehicle; and the NSX Concept, which presages the direction for Acura’s next-generation supercar.
Acura also announced that the next-generation NSX will feature Acura’s innovative new Sport Hybrid SH-AWD® technology and that the vehicle will be developed by Honda R&D Americas and manufactured in Ohio.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/acura/45743/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
When a life-changing diagnosis brings moments of uneasiness, a glimmer of hope can make all the difference in bringing solace. As hope comes in many forms, Extended Stay America® hotels, the nation’s largest owner operated hotelier, announced today the launch of the brand’s latest initiative in their continued support for the fight against cancer – the “Give Hope” program. A natural evolution of Extended Stay America’s partnership with the American Cancer Society, the “Give Hope” program provides a platform to raise awareness and funds for pediatric cancer research.
To view the multimedia release go to:
https://www.multivu.com/players/English/8060751-extended-stay-america-give-hope-cancer-research/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
On May 8, 1945 the world celebrated the end of World War II in Europe, but for some young American children it represented the beginning of a lifetime without their fathers. It’s estimated that more than 180,000 American children were left fatherless after the war. “War always leaves behind dead soldiers, grieving widows, grieving parents and children, who have suffered a loss over which they have no control,” said Geraldine Conway Morenski, whose father is buried in Netherlands American Cemetery.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7062154-netherlands-american-cemetery/
Two of the most beloved holiday icons are leveraging their celebrity this season to bring attention to heart disease – the No. 1 cause of death in the U.S. Mrs. Claus is inviting American families to join her in making the same, heart-healthy lifestyle changes she and Santa are taking on this year to raise awareness for nutrition’s role in heart health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7183432-heart-healthier-holiday-dsm/
Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes.
“Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
To view the multimedia release go to:
http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support people with diabetes and those who love them, Lilly Diabetes today announced it will donate $94,000 to the American Diabetes Association (Association) Campership program and $100,000 to the Diabetes Scholars Foundation (Foundation).
To view the multimedia release go to:
http://www.multivu.com/players/English/8004851-lilly-diabetes-scholarship-donations/
